Immatics
translational data consistent with clinical outcomes a | Immatics
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
13 of 25
Related slides by other companies
argenx SE
Investor Presentation
March 2023
steady cadence of data over next several years | argenx SE
argenx SE
Investor Presentation
March 2023
strong translational biology rationale for blockade in a | argenx SE
23andMe
Investor Presentation
January 2024
next steps | 23andMe
Kiromic BioPharma
Investor Presentation
May 2023
upcoming milestones authorization to evaluate in non small cell lung cancer may beginning of first in human trial activation for data results from first patient in clinical trial by end of initiation of clinical trials expansion cohort submission of new for and | Kiromic BioPharma
Other recent decks by Immatics
See all presentations (2 decks)
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights